vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and Xos, Inc. (XOS). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $5.2M, roughly 1.8× Xos, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -186.8%, a 187.4% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -54.5%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -35.7%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.
SSKN vs XOS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $5.2M |
| Net Profit | $58.0K | $-9.8M |
| Gross Margin | 61.8% | -50.5% |
| Operating Margin | 5.3% | -186.6% |
| Net Margin | 0.6% | -186.8% |
| Revenue YoY | -3.0% | -54.5% |
| Net Profit YoY | 101.3% | 48.6% |
| EPS (diluted) | $0.14 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $5.2M | ||
| Q3 25 | $6.9M | $16.5M | ||
| Q2 25 | $7.7M | $18.4M | ||
| Q1 25 | $6.8M | $5.9M | ||
| Q4 24 | $9.6M | $11.5M | ||
| Q3 24 | $8.8M | $15.8M | ||
| Q2 24 | $8.4M | $15.5M | ||
| Q1 24 | $6.8M | $12.6M |
| Q4 25 | $58.0K | $-9.8M | ||
| Q3 25 | $-1.6M | $2.1M | ||
| Q2 25 | $-2.6M | $-7.5M | ||
| Q1 25 | $-2.1M | $-10.2M | ||
| Q4 24 | $-4.6M | $-19.0M | ||
| Q3 24 | $-2.1M | $-10.5M | ||
| Q2 24 | $-91.0K | $-9.7M | ||
| Q1 24 | $-3.4M | $-11.0M |
| Q4 25 | 61.8% | -50.5% | ||
| Q3 25 | 60.4% | 15.3% | ||
| Q2 25 | 56.2% | 8.8% | ||
| Q1 25 | 53.5% | 20.6% | ||
| Q4 24 | 61.4% | -32.4% | ||
| Q3 24 | 60.1% | 18.1% | ||
| Q2 24 | 59.0% | 13.1% | ||
| Q1 24 | 45.6% | 22.1% |
| Q4 25 | 5.3% | -186.6% | ||
| Q3 25 | -16.9% | -42.4% | ||
| Q2 25 | -30.1% | -38.5% | ||
| Q1 25 | -25.0% | -157.7% | ||
| Q4 24 | -44.7% | -127.0% | ||
| Q3 24 | -18.2% | -61.4% | ||
| Q2 24 | -5.7% | -73.2% | ||
| Q1 24 | -42.7% | -81.1% |
| Q4 25 | 0.6% | -186.8% | ||
| Q3 25 | -23.4% | 12.9% | ||
| Q2 25 | -33.6% | -40.8% | ||
| Q1 25 | -31.2% | -173.3% | ||
| Q4 24 | -47.6% | -165.4% | ||
| Q3 24 | -23.6% | -66.6% | ||
| Q2 24 | -1.1% | -62.2% | ||
| Q1 24 | -49.8% | -87.1% |
| Q4 25 | $0.14 | $-0.76 | ||
| Q3 25 | $-0.36 | $0.22 | ||
| Q2 25 | $-0.62 | $-0.91 | ||
| Q1 25 | $-0.51 | $-1.26 | ||
| Q4 24 | $-2.01 | $-2.34 | ||
| Q3 24 | $-0.51 | $-1.32 | ||
| Q2 24 | $-0.03 | $-1.23 | ||
| Q1 24 | $-0.10 | $-1.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $14.0M |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $23.3M |
| Total Assets | $30.5M | $60.4M |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $14.0M | ||
| Q3 25 | $7.1M | $14.1M | ||
| Q2 25 | $6.0M | $8.8M | ||
| Q1 25 | $6.5M | $4.8M | ||
| Q4 24 | $7.3M | $11.0M | ||
| Q3 24 | $7.1M | $8.4M | ||
| Q2 24 | $5.5M | $19.7M | ||
| Q1 24 | $5.2M | $46.2M |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | $23.3M | ||
| Q3 25 | $1.3M | $31.1M | ||
| Q2 25 | $532.0K | $18.3M | ||
| Q1 25 | $3.0M | $24.8M | ||
| Q4 24 | $5.0M | $33.6M | ||
| Q3 24 | $9.4M | $50.8M | ||
| Q2 24 | $9.5M | $59.2M | ||
| Q1 24 | $9.4M | $67.8M |
| Q4 25 | $30.5M | $60.4M | ||
| Q3 25 | $30.7M | $73.8M | ||
| Q2 25 | $29.5M | $80.3M | ||
| Q1 25 | $33.0M | $87.7M | ||
| Q4 24 | $34.9M | $98.3M | ||
| Q3 24 | $39.4M | $120.5M | ||
| Q2 24 | $38.8M | $123.4M | ||
| Q1 24 | $39.2M | $135.0M |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $2.4M |
| Free Cash FlowOCF − Capex | $-551.0K | — |
| FCF MarginFCF / Revenue | -5.9% | — |
| Capex IntensityCapex / Revenue | 3.4% | 0.0% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $2.4M | ||
| Q3 25 | $-64.0K | $3.1M | ||
| Q2 25 | $-1.9M | $4.6M | ||
| Q1 25 | $-550.0K | $-4.8M | ||
| Q4 24 | $703.0K | $3.3M | ||
| Q3 24 | $-302.0K | $-11.5M | ||
| Q2 24 | $591.0K | $-26.0M | ||
| Q1 24 | $-804.0K | $-14.6M |
| Q4 25 | $-551.0K | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $-2.0M | — | ||
| Q1 25 | $-749.0K | — | ||
| Q4 24 | $199.0K | — | ||
| Q3 24 | $-364.0K | $-11.7M | ||
| Q2 24 | $246.0K | $-26.1M | ||
| Q1 24 | $-1.5M | $-14.6M |
| Q4 25 | -5.9% | — | ||
| Q3 25 | -15.6% | — | ||
| Q2 25 | -26.1% | — | ||
| Q1 25 | -11.0% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | -4.1% | -73.9% | ||
| Q2 24 | 2.9% | -168.1% | ||
| Q1 24 | -22.6% | -115.7% |
| Q4 25 | 3.4% | 0.0% | ||
| Q3 25 | 14.7% | 0.0% | ||
| Q2 25 | 0.8% | 0.0% | ||
| Q1 25 | 2.9% | 0.0% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 0.7% | 0.9% | ||
| Q2 24 | 4.1% | 0.8% | ||
| Q1 24 | 10.7% | 0.2% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
XOS
Segment breakdown not available.
